SR9009

Also known as: Stenabolic

Rev-ErbA agonist

What is SR9009?

SR9009, also known as Stenabolic, is a synthetic compound categorized under fat loss and metabolic peptides. It functions primarily as a Rev-ErbA agonist, influencing metabolic processes in the body. This peptide has gained attention in research for its potential effects on metabolism, endurance, and fat loss.

How It Works

SR9009 operates by activating the Rev-ErbA protein, which plays a crucial role in regulating circadian rhythms and metabolic functions. By binding to this protein, SR9009 can enhance the body’s ability to burn fat and improve overall energy expenditure. This mechanism is thought to influence various metabolic pathways, including lipid metabolism and glucose homeostasis.

Metabolic Regulation

The activation of Rev-ErbA leads to increased mitochondrial biogenesis and improved muscle performance, contributing to enhanced endurance and fat oxidation.

Research Uses

  • Fat Loss

    Investigated for its potential to promote fat loss by increasing metabolic rates.
  • Endurance Enhancement

    Studied for its effects on physical performance and stamina during exercise.
  • Circadian Rhythm Regulation

    Explored for its role in maintaining healthy sleep-wake cycles and metabolic timing.
  • Cardiovascular Health

    Research indicates potential benefits in heart health through improved lipid profiles.

Effects

  • Increased Fat Oxidation

    Users report enhanced fat burning, particularly during exercise.
  • Improved Endurance

    Research suggests significant gains in stamina and physical performance.
  • Enhanced Recovery

    Some studies indicate quicker recovery times post-exercise.
  • Regulated Blood Sugar Levels

    Observations show potential stabilization of glucose levels in some subjects.

Summary

SR9009 is a peptide with significant implications in metabolic regulation and fat loss. Its role as a Rev-ErbA agonist positions it as a valuable subject for research in enhancing endurance and metabolic health.

Last updated: Feb 25, 2026